Neogen Co. (NASDAQ:NEOG) CEO John Edward Adent Purchases 14,500 Shares

Neogen Co. (NASDAQ:NEOG) CEO John Edward Adent bought 14,500 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The stock was purchased at an average cost of $13.80 per share, with a total value of $200,100.00. Following the completion of the purchase, the chief executive officer now directly owns 216,477 shares of the company’s stock, valued at $2,987,382.60. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neogen Stock Performance

NEOG stock traded up $0.68 during midday trading on Tuesday, reaching $14.70. 260,393 shares of the company were exchanged, compared to its average volume of 1,960,685. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of 1,402.00 and a beta of 1.21. The business has a 50-day moving average price of $16.18 and a two-hundred day moving average price of $15.18. Neogen Co. has a one year low of $11.46 and a one year high of $20.89. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.82 and a quick ratio of 2.59.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Thursday, October 10th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $217.00 million for the quarter, compared to analyst estimates of $215.05 million. Neogen had a positive return on equity of 3.09% and a negative net margin of 1.02%. The company’s revenue was down 5.2% on a year-over-year basis. During the same quarter last year, the business earned $0.11 earnings per share. Equities research analysts forecast that Neogen Co. will post 0.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on NEOG shares. Piper Sandler increased their price target on shares of Neogen from $17.00 to $17.50 and gave the company a “neutral” rating in a research note on Tuesday, August 6th. StockNews.com upgraded shares of Neogen to a “sell” rating in a research note on Monday, September 30th.

Hedge Funds Weigh In On Neogen

Several institutional investors and hedge funds have recently modified their holdings of NEOG. Vanguard Group Inc. raised its position in shares of Neogen by 9.3% in the fourth quarter. Vanguard Group Inc. now owns 19,546,737 shares of the company’s stock valued at $393,085,000 after buying an additional 1,663,125 shares in the last quarter. Moody National Bank Trust Division bought a new position in shares of Neogen in the first quarter worth $161,000. Bridge City Capital LLC raised its stake in Neogen by 0.8% in the first quarter. Bridge City Capital LLC now owns 177,204 shares of the company’s stock valued at $2,796,000 after purchasing an additional 1,389 shares in the last quarter. Northwest Investment Counselors LLC grew its stake in Neogen by 1.1% during the first quarter. Northwest Investment Counselors LLC now owns 71,621 shares of the company’s stock worth $1,130,000 after buying an additional 809 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in Neogen by 25.6% in the 1st quarter. Diversified Trust Co now owns 47,629 shares of the company’s stock valued at $752,000 after buying an additional 9,707 shares during the period. 96.73% of the stock is currently owned by institutional investors and hedge funds.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.